Novadip Biosciences

11 articles about Novadip Biosciences

• Novadip Biosciences SA announces significant clinical milestones for both of its clinical-stage programs

  12/5/2023

  Novadip Biosciences SA announced that the first US patient has been implanted with its investigational tissue regeneration product, NVD-003, in its Phase 1b/2a clinical trial in Congenital Pseudarthrosis of Tibia, a rare pediatric bone condition.

• Novadip Biosciences SA Announces First Pediatric Patient with Congenital Pseudoarthrosis of the Tibia Undergoes Implantation with NVD-003, an Autologous Tissue Regeneration Product, in Phase 1b/2a US/EU Clinical Trial

  5/17/2023

  Novadip Biosciences SA today announced that the first patient has been implanted with its investigational tissue regeneration product, NVD-003, in its Phase 1b/2a clinical trial treating four patients with Congenital Pseudarthrosis of Tibia (CPT).

• Novadip Biosciences SA Appoints Judy Ashworth, MD, as Chief Medical Officer

  12/27/2022

  Novadip Biosciences SA announced the appointment of Judy Ashworth, MD, as Chief Medical Officer of the Company.

• Novadip Biosciences SA Announces Positive Results from Phase 1/2 Clinical Trial in Patients with Severe Bone Non-Union of the Lower Limb Following Trauma

  12/8/2022

  Novadip Biosciences SA announced positive data from its Phase 1/2 clinical trial evaluating the safety and clinical activity of its investigational product, NVD-003, in patients with severe bone non-union of the lower limb following trauma.

• Novadip Biosciences Raises Additional EUR 40 Million Bringing Total Company Funding to EUR 88 Million

  11/3/2022

  Novadip Biosciences announced that it has raised an additional EUR 40 million in a Series B equity round and non-dilutive funding.

• Novadip Biosciences announces EUR 19 million Series B financing backed by international investors

  10/28/2021

  Novadip Biosciences today announced that it has raised €19 million in the first close of a Series B financing

• Novadip Biosciences reports positive data from phase I study of NVD-001 for spinal fusion

  6/15/2021

  Mont-Saint-Guibert, June 15, 2021 - Novadip Biosciences, a clinical stage company developing treatments to regenerate impaired tissues in patients with significant unmet medical needs, announced positive final results from a Phase I study of its autologous cell-based product, NVD-001, in patients needing single-level spinal fusion.

• Novadip Biosciences Presents Clinical Case Study on Next Generation Tissue Regeneration Therapy for Critical Size Bone Reconstruction at EORS Conference

  10/2/2019

  Novadip Biosciences will present a case study highlighting the results of a scaffold-free, 3-dimensional autologous cell therapy for the treatment of critical size bone reconstruction at the European Orthopaedic Research Society 2019 conference in Maastricht, The Netherlands.

• Novadip Biosciences presents poster at 11th annual The Bioprocessing Summit

  8/12/2019

  Presentation to focus on manufacturing platform for tissue engineering

• NOVADIP BIOSCIENCES appoints Jeff Abbey as CEO

  12/12/2018

  NOVADIP BIOSCIENCES announces that Jeff Abbey will be appointed chief executive officer, effective early 2019, succeeding Jean-François Pollet.

• Novadip Biosciences Appoints Eric Paul Pâques As Chairman Of The Board

  5/30/2017